Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 11
Submit an article Journal homepage
3,112
Views
6
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore

Mohamed Ismail Abdul Aziza Agency for Care Effectiveness, Ministry of Health, Singapore, SingaporeORCID Iconhttps://orcid.org/0000-0003-3606-7672
ORCID Icon,
Wayne Yong Xiang Fooa Agency for Care Effectiveness, Ministry of Health, Singapore, Singapore
,
Chee Keong Tohb Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
,
Wan-Teck Limb Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
&
Kwong Nga Agency for Care Effectiveness, Ministry of Health, Singapore, SingaporeCorrespondence[email protected]
Pages 1330-1339 | Received 23 Jun 2020, Accepted 18 Aug 2020, Published online: 21 Sep 2020

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Joo-Young Byun, Sun-Kyeong Park, Boon Peng Ng, Yi-Shao Liu, Chae-Rin Kim & Chanhyun Park. (2022) A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opinion on Pharmacotherapy 23:11, pages 1247-1257.
Read now

Articles from other publishers (5)

Rihua Cheng, Zhen Zhou & Qiao Liu. (2023) The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China. Advances in Therapy 40:10, pages 4298-4309.
Crossref
Mousa Alali & Maher Saifo. (2023) Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review. Journal of Immunotherapy and Precision Oncology 6:3, pages 140-149.
Crossref
Ying-Yuan Chen, Po-Lan Su, Wei-Li Huang, Chao-Chun Chang, Yi-Ting Yen, Chien-Chung Lin & Yau-Lin Tseng. (2022) The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study. Scientific Reports 12:1.
Crossref
Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu & Qilin Zhang. (2022) Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China. Frontiers in Pharmacology 13.
Crossref
Hideo Kunitoh. (2022) Publishing inconvenient data. Japanese Journal of Clinical Oncology 52:5, pages 403-404.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.